Abstract
Introduction/Aim: Acute promyelocytic leukemia (APL) has the highest risk for overt disseminated intravascular coagulopathy (DIC), with reported incidence of DIC up to 90%, compared to 10-40% in other AML types. The influence of DIC on early death in non-APL AML patients is not evaluated so far. Aim of our study was to analyze of the incidence of DIC in non-APL AML, its clinical and laboratory characteristics, and impact on survival and early death of patients with non-APL AML.
Methods: Total of 176 patients with non-APL AML diagnosed and treated at the Clinic of Hematology Clinical Center Serbia between 2015-2020 were evaluated retrospectively. The diagnosis of DIC was made on the basis of ISTH (International Society on Thrombosis and Haemostasis) criteria.
Results: Mean age of our patients was 53.8 ± 14.6 year, 99/176 (56.2%) were men. DIC was present in 74/176 (42.05%) patients who had significant prevalence of hemorrhagic syndrome (p = 0.01). Risk factors for overt DIC were: older age (p <0.01), comorbidities (p = 0.01), leukocytosis (p <0.001) and high LDH (p <0.001). FAB type of non-APL AML, cytogenetic risk group, and CD56 had no influence on overt DIC (p> 0.05). No difference was found in early mortality, outcome, and survival of non-APL AML patients with and without DIC (p> 0.05).
Conclusion: Older age at diagnosis, comorbidities, leukocytosis, and high LDH concentrations are found to be the adverse risk factors for overt DIC in non-APL AML patients. If treated promptly with immediate, adequate and intensive use of blood derivates and components, DIC has no negative impact on early mortality, outcome, and survival.
Keywords
Array
Array
Array